Navigation Links
Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
Date:1/22/2008

TORONTO, Jan. 22 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. (TSX: LOR; AMEX: LRP), a biopharmaceutical company dedicated in the research and development of pharmaceutical products and technologies for the management of cancer, announced today that it has strengthened its management team with the appointment of Mr. Peter Korth to the post of Chief Financial Officer (CFO).

Mr. Korth has previously held senior financial and business development positions including CFO in several private and public companies including DRI Capital (formerly known as Drug Royalty Corp.), Clean Power Income Fund, TransAlta Corporation and Indal Limited where he has been responsible for capital and credit markets, transaction structuring, managing subsidiary reorganizations, risk management practices as well as international business development in Asia and Australia.

"Mr. Korth brings significant expertise in corporate finance, investor relations, corporate governance and compliance to the management team at Lorus," said Dr. Aiping Young, Lorus' President and CEO. "We believe Lorus will benefit from Peter's track record in developing and bringing an exemplary combination of business judgment, professional skills and integrity."

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of novel therapeutics in cancer. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination with other drugs, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Lorus has completed one Phase II and one Phase III clinical trial. Lorus Therapeutics Inc. is listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP.

Forward looking statements '/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
4. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
5. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
6. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
7. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
8. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
9. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
10. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
11. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)... , CAMBRIDGE, Mass., Dec. 1 /PRNewswire...logy industry and to promote its potential, a grou...tion of the Synthetic Biology Industry Association...he goal of the association is to provide a forum f... the new industry, address its opportunities and i...
(Date:12/1/2009)... , SPRINGFIELD, Ill., Dec. 1 /PRNewswire/ -...roud to announce that it was recently awarded two ...s event on Nov. 13 in New York City. The CLIO Heal...nnovation in the healthcare advertising industry a...world,s most recognized awards competitions for ad...
(Date:12/1/2009)... Congruent Software agrees to ...ding project accounting clients) to Synergy Busine... Seattle, WA (PRWEB) December 1,...y it has acquired the Microsoft Dynamics SL practi...technology provider. The move was necessary due to...
(Date:12/1/2009)... , INDIANAPOLIS and NORTH VANCOUVER, British ...oSciences LLC, a wholly owned subsidiary of The Do...osciences, Inc. today announced the signing of a r...he agreement provides Dow AgroSciences with access...ETL) technology on an exclusive basis in major foo...
Breaking Biology Technology:Industry Forms Association to Address Opportunities and Challenges of Synthetic Biology 2Prairie Heart Institute of Illinois Wins Two CLIO Healthcare Awards 2Synergy Business Solutions Acquires the Microsoft Dynamics SL Practice of Congruent Software, Inc. 2Synergy Business Solutions Acquires the Microsoft Dynamics SL Practice of Congruent Software, Inc. 3Dow AgroSciences, Agrisoma Biosciences Announce Research and Commercial License Option Agreement for Agricultural Crops 2Dow AgroSciences, Agrisoma Biosciences Announce Research and Commercial License Option Agreement for Agricultural Crops 3
...onths Compared with Fiscal 2007,Net Income To Comm...Quarter, MOUNTAIN VIEW, Calif., Jan. 24 Pharsigh... of software and strategic,services designed to op...financial results for its third quarter of fiscal ...d quarter was $7.4 million, a 20% increase,compare...
... 11-13 at the Waldorf-Astoria Hotel in New York ...n. 24 Gerson Lehrman Group (GLG) and the,Biotechn...a collaborative,agreement designed to strengthen t...the tenth annual BIO CEO & Investor Conference., ...portunity with BIO in,their tireless efforts to in...
...ua-PRNewswire/ -- Chindex International,Inc. (Nasd...r of Western,healthcare services and products in t...t Lawrence Pemble, CFO is scheduled to make a pres...s Conference taking place February,14-16 at The Gr...tion is scheduled to begin at 4:30 p.m. (EST) on,T...
Other Biology Technology:Pharsight Achieves $7.4 Million in Quarterly Revenue 2Pharsight Achieves $7.4 Million in Quarterly Revenue 3Pharsight Achieves $7.4 Million in Quarterly Revenue 4Pharsight Achieves $7.4 Million in Quarterly Revenue 5Pharsight Achieves $7.4 Million in Quarterly Revenue 6Pharsight Achieves $7.4 Million in Quarterly Revenue 7Pharsight Achieves $7.4 Million in Quarterly Revenue 8Pharsight Achieves $7.4 Million in Quarterly Revenue 9Pharsight Achieves $7.4 Million in Quarterly Revenue 10Pharsight Achieves $7.4 Million in Quarterly Revenue 11Pharsight Achieves $7.4 Million in Quarterly Revenue 12Gerson Lehrman Group Announces Partnership With BIO to Provide Scientific Expertise for the BIO CEO & Investor Conference 2Gerson Lehrman Group Announces Partnership With BIO to Provide Scientific Expertise for the BIO CEO & Investor Conference 3Chindex International, Inc. to Present at 2008 UBS Global Healthcare Services Conference 2Chindex International, Inc. to Present at 2008 UBS Global Healthcare Services Conference 3
(Date:12/1/2009)...cularly in Alzheimer,s disease, nerve cell degener...rapeutic options may possibly be derived from stee...ese findings have been published in the current is... Until only a few years ago, neurogenesis the pro...be impossible in the adult brain. The textbooks as...
(Date:12/1/2009)...ly the scientists, one from the United States, the...utus, the leader of his wolf pack, on remote Elles...heir goal to finally find out what these "North P... one of the harshest areas of the world., "We fi...aid David Mech, a renowned U.S. Geological Survey ...
(Date:12/1/2009)...arles Darwin it was an ,abominable mystery, and it...nists to this day: when did flowering plants evolv...earth? Today a study in Ecology Letters reveals ...ing plants gaining a major competitive advantage o...m and abundance. , The study, by Dr Tim Brodribb...
Breaking Biology News(10 mins):New source discovered for the generation of nerve cells in the brain 2North Pole wolf emails locations to researchers 2North Pole wolf emails locations to researchers 3How did flowering plants evolve to dominate Earth? 2Healthcare Travel Congress 2009 3A Experts Worldwide Convene in Singapore For Regional Conference on Medical Tourism 48752 1Healthcare Travel Congress 2009 3A Experts Worldwide Convene in Singapore For Regional Conference on Medical Tourism 48752 2Healthcare Travel Congress 2009 3A Experts Worldwide Convene in Singapore For Regional Conference on Medical Tourism 48752 3Tasty Baking Company Supports the Fight Against Childhood Cancer Through Partnership with Alexs Lemonade Stand Foundation 48750 1Tasty Baking Company Supports the Fight Against Childhood Cancer Through Partnership with Alexs Lemonade Stand Foundation 48750 2Tasty Baking Company Supports the Fight Against Childhood Cancer Through Partnership with Alexs Lemonade Stand Foundation 48750 3Preparing the Americas 3A The Outlook for 2009s Emergency Threats 48748 1Preparing the Americas 3A The Outlook for 2009s Emergency Threats 48748 2
...rom climate change will reach a tipping point in l... in the health of the planet,s coral reef ecosyste...eport issued today. , Released by the Global Cor...oral Reef Initiative, international governmental a... of the World: 2008" provides both good and bad ne...
...ons are the Clark Kents of a genome. Apparently mi...rsts of activity, these free-floating bits of gene...ing into the genetic maps of plants and animals, d...rs, researchers thought that most of this DNA was ...ngs, however, are peeling back the odd and bafflin...
...able in French . , Montreal, December 10th, 20...ter weight gain during puberty, according to a new...rinology & Metabolism . Even in sun-drenched Calif... Health Centre (MUHC) and the University of Southe...iciency was found to cause higher body mass and sh...
Other Biology News:Time running out on coral reefs as climate change becomes increasing threat 2Time running out on coral reefs as climate change becomes increasing threat 3New research shows how gene function drives natural selection in important class of genetic elements 2New research shows how gene function drives natural selection in important class of genetic elements 3Lack of vitamin D causes weight gain and stunts growth in girls 2
Streptavidin, PE conjugated/tagged from Invitrogen
Supercoiled DNA Ladder from Invitrogen
GIBCO RPMI Medium 1640; powder from Invitrogen
Rabbit Anti-Human Parathyroid Hormone Receptor 2 Polyclonal Antibody, Unconjugated from Abcam
Biology Products: